Nemocnice Havlickuv Brod p.o.
- Address
- Husova 2624, 580 01 Havlíčkův Brod, Czechia
Nemocnice Havlickuv Brod p.o. - Heart Failure Research Center
Nemocnice Havlickuv Brod p.o. is a medical research facility contributing to advanced cardiovascular research, with particular emphasis on innovative therapeutic approaches for patients with complex cardiac conditions. The center participates in clinical investigations examining novel combination therapies aimed at improving outcomes for individuals with preserved or mildly reduced ejection fraction.
- Heart failure with preserved ejection fraction (HFpEF) and mildly reduced ejection fraction
- Novel pharmacological combinations including vicadrostat and empagliflozin therapy
- Prevention of cardiovascular death, heart failure hospitalization, and urgent heart failure visits
The research conducted at this institution focuses on evaluating combination drug therapies that address the multifaceted pathophysiology of heart failure. Through participation in phase III clinical trials, the center contributes valuable data on treatment strategies designed to reduce major cardiac events and improve quality of life for patients with LVEF ≥40%, representing a significant patient population with substantial unmet medical needs.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Nemocnice Havlickuv Brod p.o.
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Efepoetin Alfa Versus Darbepoetin Alfa in Anemia Management for Chronic Kidney Disease Patients on Dialysis | Genexine Inc. | Phase III | Recruiting | Jul 2025 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bi 690517 | 1 | Unknown | 2024-10-18 | 2024-10-18 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.